Category: Pharma, Life Sciences & Med Tech Players
-
Abbott wins another UPC PI against glucose sensor rival Sibio
The UPC’s Milan Local Division has granted Abbott a second UPC-wide preliminary injunction in its patent infringement case against Chinese rival Sibio, despite allowing the latter’s late-presented claim construction arguments to be admitted.
-
Accord slapped with injunction in Munich after invalidity losses in EPO, German Federal Patent CourtÂ
The Munich I Regional Court has found that Accord infringed TOWA’s dabigatran etexilate patent, issuing an injunction against the company. Dabigatran etexilate is an oral anticoagulant medicine that stops blood clots from forming, preventing strokes, deep vein thrombosis, and pulmonary embolism, among other things.
-
Lupin granted win against Vertex in Delaware over cystic fibrosis drug patents
Lupin’s generic version of Vertex’s cystic fibrosis treatment Kalydeco does not infringe the latter’s patents, Judge Stephanos Bibas of the Third Circuit has ruled.
-
FTC urges Fourth Circuit to reject Amgen plea to shield Roche patent acquisition: deal “threatens to upend” long-settled antitrust framework
The U.S. Federal Trade Commission has filed an amicus brief in an antitrust case between CareFirst and Amgen, urging the Fourth Circuit to reject Amgen’s bid to shield its acquisition of pending patent applications from antitrust scrutiny, as such procurements violate the Sherman Act and are not immunized by the Noerr-Pennington doctrine.
-
UPC Court of Appeal upholds Abbott’s glucose sensor patent: rejects Sibio’s added matter, inventive step attacks
The UPC Court of Appeal has dismissed Sibio’s bid to revoke Abbott’s continuous glucose monitor patent, confirming its own earlier finding from a related injunction case and issuing two headnotes that will guide how the court treats omitted features in future added matter disputes.
-
China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledgeÂ
A Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. China’s top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.
-
EWHC hinders Accord’s plans to launch Entresto competing product in Novartis patent dispute
Mr. Justice Meade of the High Court of Justice for England & Wales has held that all of Accord’s “attacks” on a Novartis Entresto patent have failed, and its own intended competing product would infringe the defendant’s supplementary protection certificate.
-
UPC Munich LD flags novel questions on damages law in Edwards v. Meril damages claim, flags novel questions on applicable law and non-infringing substitute profits
At an interim hearing, the Munich LD set Edwards’ damages claim against Meril at a €15 million value in dispute and previewed how it may rule on two open legal questions.
-
Patent Litigation Europe returns for 2027, building on last year’s rebrand into three co-located tracksÂ
Speakers already confirmed for the event include Hon. Emmanuel Gouge and Aleš Zalar of the UPC, Judge Oliver Schön of the Munich Regional Court, Abbott’s Gael Tisack, Ericsson’s Gabriele Mohsler, Nokia’s Clemens Heusch, and SIM IP’s Erich Spangenberg.
-
China’s top court hands U.S. patentee landmark patent damages award
U.S. insecticide producer FMC Agriculture Singapore has been awarded a record of nearly 33 million Chinese yuan ($4.84 million) in patent infringement damages in a decision in which the defendant’s legal representative has also been found jointly liable – a rarity in Chinese IP infringement cases.